The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation
Open accessAbstract
BACKGROUND: Transplant recipients in whom cutaneous squamous-cell carcinomas develop are at high risk for multiple subsequent skin cancers. Whether sirolimus is useful in the prevention of secondary skin cancer has not been assessed. METHODS: In this multicenter trial, we randomly assigned transplant recipients who were taking calcineurin inhibitors and had at least one cutaneous squamous-cell carcinoma either to receive sirolimus as a substitute for calcineurin inhibitors (in 64 patients) or to maintain their initial treatment (in 56). The primary end point was survival free of squamous-cell carcinoma at 2 years. Secondary end points included the time until the onset of new squamous-cell carcinomas, occurrence of other skin tumors, graft function, and problems with sirolimus. RESULTS: Survival free of cutaneous squamous-cell carcinoma was significantly longer in the sirolimus group than in the calcineurin-inhibitor group. Overall, new squamous-cell carcinomas developed in 14 patients (22%) in the sirolimus group (6 after withdrawal of sirolimus) and in 22 (39%) in the calcineurin-inhibitor group (median time until onset, 15 vs. 7 months; P=0.02), with a relative risk in the sirolimus group of 0.56 (95% confidence interval, 0.32 to 0.98). There were 60 serious adverse events in the sirolimus group, as compared with 14 such events in the calcineurin-inhibitor group (average, 0.938 vs. 0.250). There were twice as many serious adverse events in patients who had been converted to sirolimus with rapid protocols as in those with progressive protocols. In the sirolimus group, 23% of patients discontinued the drug because of adverse events. Graft function remained stable in the two study groups. CONCLUSIONS: Switching from calcineurin inhibitors to sirolimus had an antitumoral effect among kidney-transplant recipients with previous squamous-cell carcinoma. These observations may have implications concerning immunosuppressive treatment of patients with cutaneous squamous-cell carcinomas. (Funded by Hospices Civils de Lyon and others; TUMORAPA ClinicalTrials.gov number, NCT00133887.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Skin cancers after organ transplantation
Euvrard, S., Kanitakis, J., & Claudy, A. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022137 · Cited by 1,575
Self-citationSirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
Cyclosporine induces cancer progression by a cell-autonomous mechanism
Hojo, M., Morimoto, T., Maluccio, M., Asano, T., Morimoto, K., Lagman, M., Shimbo, T., & Suthanthiran, M. (1999) · Nature · doi:10.1038/17401 · Cited by 1,149
Dantal, J., Hourmant, M., Cantarovich, D., Giral, M., Blancho, G., Dreno, B., & Soulillou, J.-P. (1998) · The Lancet · doi:10.1016/s0140-6736(97)08496-1 · Cited by 745
Self-citationKauffman, H. M., Cherikh, W. S., Cheng, Y., Hanto, D. W., & Kahan, B. D. (2005) · Transplantation · doi:10.1097/01.tp.0000184006.43152.8d · Cited by 621
Schena, F. P., Pascoe, M. D., Alberu, J., del Carmen Rial, M., Oberbauer, R., Brennan, D. C., Campistol, J. M., Racusen, L., Polinsky, M. S., Goldberg-Alberts, R., et al. (2009) · Transplantation · doi:10.1097/tp.0b013e3181927a41 · Cited by 583
Self-citationSirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Serra, A. L., Poster, D., Kistler, A. D., Krauer, F., Raina, S., Young, J., Rentsch, K. M., Spanaus, K. S., Senn, O., Kristanto, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907419 · Cited by 571
Self-citationCampistol, J. M., Eris, J., Oberbauer, R., Friend, P., Hutchison, B., Morales, J. M., Claesson, K., Stallone, G., Russ, G., Rostaing, L., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005090993 · Cited by 478
Self-citationPRO- AND ANTI-CANCER EFFECTS OF IMMUNOSUPPRESSIVE AGENTS USED IN ORGAN TRANSPLANTATION
Guba, M., Graeb, C., Jauch, K.-W., & Geissler, E. K. (2004) · Transplantation · doi:10.1097/01.tp.0000120181.89206.54 · Cited by 360
Budde, K., Becker, T., Arns, W., Sommerer, C., Reinke, P., Eisenberger, U., Kramer, S., Fischer, W., Gschaidmeier, H., & Pietruck, F. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62318-5 · Cited by 359
Mathew, T., Kreis, H., & Friend, P. (2004) · Clinical Transplantation · doi:10.1111/j.1399-0012.2004.00188.x · Cited by 307
Opposing roles for calcineurin and ATF3 in squamous skin cancer
Wu, X., Nguyen, B.-C., Dziunycz, P., Chang, S., Brooks, Y., Lefort, K., Hofbauer, G. F. L., & Dotto, G. P. (2010) · Nature · doi:10.1038/nature08996 · Cited by 292
Self-citationSkin Cancer in Organ Transplant Recipients—Where Do We Stand Today?
Ulrich, C., Kanitakis, J., Stockfleth, E., & Euvrard, S. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02386.x · Cited by 278
Self-citationTacrolimus enhances transforming growth factor-β1 expression and promotes tumor progression
Maluccio, M., Sharma, V., Lagman, M., Vyas, S., Yang, H., Li, B., & Suthanthiran, M. (2003) · Transplantation · doi:10.1097/01.tp.0000081399.75231.3b · Cited by 278
Kibel, A. S. (2009) · Yearbook of Urology · doi:10.1016/s0084-4071(09)79253-x · Cited by 266
Immunosuppressive Drugs and the Risk of Cancer after Organ Transplantation
Dantal, J., & Soulillou, J.-P. (2005) · New England Journal of Medicine · doi:10.1056/nejme058018 · Cited by 256
Self-citationLong-Term Benefits with Sirolimus-Based Therapy after Early Cyclosporine Withdrawal
Kreis, H., Oberbauer, R., Campistol, J. M., Mathew, T., Daloze, P., Schena, F. P., Burke, J. T., Brault, Y., Gioud-Paquet, M., Scarola, J. A., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000113248.59077.76 · Cited by 225
Self-citationAlberú, J., Pascoe, M. D., Campistol, J. M., Schena, F. P., Rial, M. D. C., Polinsky, M., Neylan, J. F., Korth-Bradley, J., Goldberg-Alberts, R., & Maller, E. S. (2011) · Transplantation · doi:10.1097/tp.0b013e3182247ae2 · Cited by 224
Self-citationSalgo, R., Gossmann, J., Schöfer, H., Kachel, H. G., Kuck, J., Geiger, H., Kaufmann, R., & Scheuermann, E. H. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02997.x · Cited by 223
Koehl, G. E., Andrassy, J., Guba, M., Richter, S., Kroemer, A., Scherer, M. N., Steinbauer, M., Graeb, C., Schlitt, H. J., Jauch, K.-W., et al. (2004) · Transplantation · doi:10.1097/00007890-200405150-00002 · Cited by 222
Campbell, S. B., Walker, R., Tai, S. S., Jiang, Q., & Russ, G. R. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04004.x · Cited by 221
Spangle, J. M., & Münger, K. (2010) · Journal of Virology · doi:10.1128/jvi.00974-10 · Cited by 189
Euvrard, S., Kanitakis, J., Decullier, E., Butnaru, A. C., Lefrançois, N., Boissonnat, P., Sebbag, L., Garnier, J.-L., Pouteil-Noble, C., Cahen, R., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000209921.60305.d9 · Cited by 171
Self-citationProby, C. M., Harwood, C. A., Neale, R. Ε., Green, A. C., Euvrard, S., Naldi, L., Tessari, G., Feltkamp, M. C. W., de Koning, M. N. C., Quint, W. G. V., et al. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03589.x · Cited by 134
Self-citationRapamycin-Resistant mTORC1 Kinase Activity Is Required for Herpesvirus Replication
Moorman, N. J., & Shenk, T. E. (2010) · Journal of Virology · doi:10.1128/jvi.02733-09 · Cited by 124
mTOR, Cancer and Transplantation
Geissler, E. K., Schlitt, H. J., & Thomas, G. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02391.x · Cited by 123
Organ transplantation and skin cancer: basic problems and new perspectives
Hofbauer, G. F. L., Bavinck, J. N. B., & Euvrard, S. (2010) · Experimental Dermatology · doi:10.1111/j.1600-0625.2010.01086.x · Cited by 118
Self-citationReduction of Immunosuppression for Transplant-Associated Skin Cancer
Otley, C. C., & Maragh, S. L. H. (2005) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2005.31038 · Cited by 84
Clippinger, A. J., Maguire, T. G., & Alwine, J. C. (2011) · Journal of Virology · doi:10.1128/jvi.01913-10 · Cited by 82
Nichols, L. A., Adang, L. A., & Kedes, D. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014535 · Cited by 79
Duncan, F. J., Wulff, B. C., Tober, K. L., Ferketich, A. K., Martin, J. R., Thomas‐Ahner, J. M., Allen, S. D., Kusewitt, D. F., Oberyszyn, T. M., & VanBuskirk, A. M. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.02004.x · Cited by 53
de Gruijl, F. R., Koehl, G. E., Voskamp, P., Strik, A. S., Rebel, H. G., Gaumann, A. K. A., de Fijter, J. W., Tensen, C. P., Bavinck, J. N. B., & Geissler, E. K. (2009) · International Journal of Cancer · doi:10.1002/ijc.25097 · Cited by 47
Rival‐Tringali, A. L., Euvrard, S., Decullier, É., Claudy, A., Faure, M., & Kanitakis, J. (2009) · PubMed · Cited by 45
Self-citationSun (1996) · doi:10.1002/(sici)1097-0258(19960715)15:13<1387::aid-sim268>3.0.co;2-r
Cited by
Guidelines of care for the management of cutaneous squamous cell carcinoma
Alam, M., Armstrong, A., Baum, C., Bordeaux, J. S., Brown, M., Busam, K. J., Eisen, D. B., Iyengar, V., Lober, C., Margolis, D. J., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.10.007 · Cited by 596
Stratigos, A., Garbe, C., Lebbe, C., Malvehy, J., del Marmol, V., Pehamberger, H., Peris, K., Becker, J. C., Zalaudek, I., Saiag, P., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.110 · Cited by 514
Self-citationCutaneous Squamous Cell Carcinoma
Waldman, A., & Schmults, C. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.08.001 · Cited by 424
Knoll, G. A., Kokolo, M. B., Mallick, R., Beck, A., Buenaventura, C. D., Ducharme, R., Barsoum, R., Bernasconi, C., Blydt-Hansen, T. D., Ekberg, H., et al. (2014) · BMJ · doi:10.1136/bmj.g6679 · Cited by 334
Charlton, M., Levitsky, J., Aqel, B., O'Grady, J., Hemibach, J., Rinella, M., Fung, J., Ghabril, M., Thomason, R., Burra, P., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002147 · Cited by 310
Metadata
- Authors
- Euvrard, S., Morelon, E., Rostaing, L., Goffin, E., Brocard, A., Tromme, I., Broeders, N., del Marmol, V., Chatelet, V., Dompmartin, A., Kessler, M., Serra, A. L., Hofbauer, G. F. L., Pouteil-Noble, C., Campistol, J. M., Kanitakis, J., Roux, A. S., Decullier, E., & Dantal, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 329-339
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1972517554
- Cited by
- 593
- References
- 36
- FWCI
- 40.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.